menu

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

    FDA oncologists discuss the approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.
    • Overview

      FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.

      Released May 22, 2017

    Facebook Comments

    You must be in to display playlists.

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.